J.K. Rowling’s rep responds to Lilly Wachowski’s accusation of ‘funding trans genocide’ (exclusive)
1 news sources are covering this Entertainment story right now — PULSE is tracking how fast it spreads.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
"J.K. Rowling’s rep responds to Lilly Wachowski’s accusation of ‘funding trans genocide’ (exclusive)" is generating significant coverage in the Entertainment category, with 1 articles from 1 distinct sources tracked by PULSE so far.
Outlets currently covering the story include Advocate.com. PULSE measures a story's velocity from how quickly new articles appear and how many independent newsrooms join the coverage.
This brief was generated by PULSE's extractive engine from coverage metadata only. The latest headlines from every source are listed below; the velocity chart shows how the story is developing in real time.
Generated by PULSE's extractive engine from coverage metadata only — no AI-written claims. Updated 65d ago.
Quick answers
Why is "J.K. Rowling’s rep responds to Lilly Wachowski’s accusation of ‘funding trans ge" trending?
Because 1 independent news sources published 1 articles about it in a short window — a coverage burst PULSE classifies as a trend.
How does PULSE measure this trend?
PULSE scores velocity from the rate of new articles weighted by source diversity, snapshotted hourly. The full method is public on our methodology page.
Is this trend still active?
The status badge on this page updates hourly: rising, peaking, cooling, or archived once coverage stops for 48 hours.
Coverage (1)
- Lilly Wachowski Says “If You Support Harry Potter, You’re Supporting Trans Genocide” Advocate.com · 67d ago
Topics
Related trends
J.K. Rowling Claims Trans Activism in the 21st Century Is ‘Elitist,’ Pens Essay Defending Her Views: They ‘Haven’t Changed’ Despite ‘Death, Rape and Torture Threats’
Author J.K. Rowling has published a new essay detailing her unchanged views on transgender activism amidst widespread coverage.
Foghorn lays off 40% of employees as Lilly cancer collab collapses over poor data
Foghorn Therapeutics cuts 40% of staff after Eli Lilly ends a cancer collaboration due to poor data.
GLP-1 makers Novo, Eli Lilly sued over sudden loss of vision in patients
Major drugmakers Novo Nordisk and Eli Lilly face numerous lawsuits alleging popular GLP-1 medications cause sudden vision loss.
Eli Lilly Stock Jumps on Monster Earnings as Finance Chief Eyes Next Growth Engine
1 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Eli Lilly CFO On Acquisition Spree: 'We Are Taking Bets' On Future Revenue
2 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
We're raising our price target on Eli Lilly as the obesity-drug boom rolls on
Eli Lilly stock reaches an all-time high amid surging GLP-1 sales and a heightened price target.